Company performance
Add to research
Current Price
as of Apr 24, 2025$62.74
P/E Ratio
28.42
Market Cap
$12.03B
Description
Add to research
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Metrics
Add to research
Overview
- HQSan Rafael, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerBMRN
- Price$62.74+1.29%
Trading Information
- Market cap$12.03B
- Float98.64%
- Average Daily Volume (1m)2,063,599
- Average Daily Volume (3m)1,671,637
- EPS$2.25
Company
- Revenue$2.84B
- Rev growth (1yr)17.35%
- Net income$426.86M
- Gross margin78.04%
- EBITDA margin22.06%
- EBITDA$626.23M
- EV$12.44B
- EV/Revenue4.38
- P/E28.42
- P/S4.35
- P/B2.12
- Debt/Equity11.48
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset